Capital Rx Ranks No. 411 on the 2024 Inc. 5000, Making the List of America's Fastest-Growing Private Companies for the Third Year

• Capital Rx continues to experience rapid growth on the back of record demand for JUDI® and its tech-enabled, full-service pharmacy benefit solutions

NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Inc. revealed today that Capital Rx, the full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA) advancing our nation's healthcare infrastructure to improve drug price visibility and patient outcomes, ranks No. 414 on the 2024 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses.

"Capital Rx's sustained growth is a direct reflection of the market's demand for an independent, modern technology platform that easily addresses the needs of today's benefit plans, but also contemplates the infrastructure required for the future of healthcare," Co-Founder & CEO AJ Loiacono said. "JUDI® addresses the growing need for plan sponsors, both large employers and health plans, to finally be given the choice to select any pharmacy network, home delivery service, rebate aggregator, point-solution, and clinical service on a secure and scalable platform."

The Inc. 5000 class of 2024 represents companies that have driven rapid revenue growth while navigating inflationary pressure, the rising costs of capital, and seemingly intractable hiring challenges. Among this year's top 500 companies, the average median three-year revenue growth rate is 1,637 percent. In all, this year's Inc. 5000 companies have added 874,458 jobs to the economy over the past three years.

"One of the greatest joys of my job is going through the Inc. 5000 list," says Mike Hofman, who recently joined Inc. as editor-in-chief. "To see all of the intriguing and surprising ways that companies are transforming sectors, from health care and AI to apparel and pet food, is fascinating for me as a journalist and storyteller. Congratulations to this year's honorees, as well, for growing their businesses fast despite the economic disruption we all faced over the past three years, from supply chain woes to inflation to changes in the workforce."

Capital Rx's JUDI is purpose-built to redefine the level of operational efficiency required to administrate Medicare, Medicaid, and commercial plans and prescription claims processing. Currently, JUDI services millions of lives and is central to Capital Rx's strategic alliance with Prime Therapeutics, which was announced earlier this year. Armed with JUDI and absent the inherent conflicts of interest associated with profiting from dispensing prescription drugs, Capital Rx is focused on delivering scalable enterprise software solutions to health plans, health systems, and other plan sponsors needing open, interoperable solutions.

For complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, location, and other criteria, go to www.inc.com/inc5000. All 5000 companies are featured on Inc.com starting Tuesday, August 13, and the top 500 appear in the new issue of Inc. magazine, available on newsstands beginning Tuesday, August 20.

Methodology
Companies on the 2024 Inc. 5000 are ranked according to percentage revenue growth from 2020 to 2023. To qualify, companies must have been founded and generating revenue by March 31, 2020. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2023. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2020 is $100,000; the minimum for 2023 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places.

About Inc.
Inc. Business Media is the leading multimedia brand for entrepreneurs. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.'s award-winning work achieves a monthly brand footprint of more than 40 million across a variety of channels, including events, print, digital, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit www.inc.com.

For more information on the Inc. 5000 Conference & Gala, to be held from October 16 to 18 in Palm Desert, California, please visit http://conference.inc.com/. 

About Capital Rx
Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. As a Certified B Corp™, Capital Rx is executing its mission through the deployment of JUDI®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. JUDI connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing millions of members for Medicare, Medicaid, and commercial plans. Together with its clients, Capital Rx is reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. To learn more, visit www.capitalrx.com.

Media Contacts

Michael Passanante, SVP, Marketing & Communications
Justin Venneri, Director, Communications
[email protected]

SOURCE Capital Rx